Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Perceived Autonomy in Performing Intravenous Injections for Patients With Severe or Moderate Hemophilia A Receiving Emicizumab (APHARIPE)

13 de noviembre de 2026 actualizado por: University Hospital, Caen

Perceived Autonomy of Patients (or Family Caregivers) With Severe or Moderate Hemophilia A for Performing Intravenous Injections Under Emicizumab Prophylaxis

Hemophilia A is a rare inherited bleeding disorder caused by a deficiency in clotting factor VIII (severe if <1%, moderate if 1% to 5%). Until the introduction of emicizumab (Hemlibra®), treatment relied exclusively on frequent intravenous (IV) infusions of clotting factor concentrates (FVIII or bypassing agents), allowing patients or their family caregivers to maintain technical skills and autonomy through regular practice.

Since 2018 (and 2023 for moderate hemophilia A), subcutaneous prophylactic treatment with emicizumab has drastically reduced bleeding episodes and, consequently, the frequency of IV infusions. However, IV injections remain necessary to treat acute breakthrough bleeds. The investigators hypothesize that previously autonomous patients or family caregivers may experience a gradual loss of skill and self-efficacy in performing IV injections while on emicizumab prophylaxis.

The APHARIPE study is a multicenter, non-interventional, exploratory study based on questionnaires administered to 450 previously autonomous patients with severe or moderate hemophilia A (or their family caregivers) receiving emicizumab, as well as their healthcare providers. Over an 18-month inclusion period, this study aims to assess perceived autonomy in performing IV injections, identify potential perception gaps between patients/caregivers and healthcare providers, evaluate the impact on acute bleed management and home emergency treatment storage, and guide future therapeutic education practices.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Descripción detallada

Hemophilia is a rare constitutional bleeding disorder. Severe hemophilia A corresponds to a severe factor VIII (FVIII) deficiency (<1%), and moderate hemophilia A to an FVIII level between 1% and 5%. Both forms manifest as spontaneous or post-traumatic/surgical intra-articular bleeds (hemarthroses) or muscle hematomas, which can jeopardize functional prognosis if recurrent.

Until April 2018, the treatment of severe and moderate hemophilia A was exclusively substitutive, relying on intravenous (IV) injections of clotting factor concentrates (FVIII, or bypassing agents such as rFVIIa or aPCC for patients with anti-FVIII inhibitors). Used both prophylactically (2 to 3 IV infusions per week) and on-demand for acute bleeds, this regimen enabled most patients-or family caregivers for younger children-to acquire and maintain autonomy in performing IV injections through frequent practice.

Since April 2018 for patients with inhibitors, March 2020 for severe hemophilia A without inhibitors, and January 2023 for moderate hemophilia A, subcutaneous prophylaxis with the monoclonal antibody emicizumab (Hemlibra®) has been available. While emicizumab converts the bleeding phenotype to that of mild hemophilia, it is strictly prophylactic; IV clotting factor infusions remain required in the event of breakthrough bleeding. Because bleeding events become very rare under emicizumab, the frequency of IV injections drops sharply.

The investigators hypothesize that patients (or family caregivers) who were previously autonomous in performing IV clotting factor infusions progressively lose technical competence and/or self-efficacy during emicizumab prophylaxis. APHARIPE is a multicenter, exploratory, non-interventional questionnaire-based study designed to evaluate patients' and caregivers' perceived loss of autonomy. Healthcare providers caring for this population will also be surveyed to assess potential perception gaps regarding the impact of this loss of autonomy on overall patient management.

The study aims to include 450 patients (or family caregivers) with severe or moderate hemophilia A treated with emicizumab who were previously autonomous for IV injections, over an 18-month recruitment period. Findings will help identify specific difficulties, question the relevance of ongoing IV injection training, assess the impact on acute bleed management and the need to keep emergency treatments at home, and ultimately optimize patient care pathways and therapeutic education practices

Tipo de estudio

De observación

Inscripción (Estimado)

450

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Nicolas GUERIN, Registered Nurse
  • Número de teléfono: + 33 2 31 06 52 10
  • Correo electrónico: guerin-n@chu-caen.fr

Ubicaciones de estudio

      • Angers, Francia, 49933
        • Centre Hospitalier Universitaire d'Angers
        • Contacto:
      • Bordeaux, Francia, 33076
        • Centre Hospitalier Universitaire de Bordeaux - Hôpital Pellegrin
        • Contacto:
      • Bron, Francia, 69677
        • Hospices Civiles de Lyon - Hôpital Louis Pradel
        • Contacto:
      • Caen, Francia, 14000
        • Centre Hospitalier Universitaire de Caen
        • Contacto:
          • Nicolas GUERIN, Registered Nurse
          • Número de teléfono: + 33 2 31 06 52 10
          • Correo electrónico: guerin-n@chu-caen.fr
      • Chambéry, Francia, 73011
        • Centre Hospitalier Métropole Savoie
        • Contacto:
      • Clermont-Ferrand, Francia, 63000
        • Centre Hospitalier Universitaire de Clermont Ferrand
        • Contacto:
      • Dijon, Francia, 21079
        • Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand
        • Contacto:
      • Grenoble, Francia
        • Centre Hospitalier Universitaire de Grenoble
        • Contacto:
          • Raphaël MARLU, Medical Doctor
          • Número de teléfono: +33 4 76 76 54 87
          • Correo electrónico: RMarlu@chu-grenoble.fr
      • Le Kremlin-Bicêtre, Francia, 94275
        • AP-HP - Hôpital Bicêtre
        • Contacto:
          • Roseline D'OIRON, Medical Doctor
          • Número de teléfono: +33 1 45 21 21 97
          • Correo electrónico: roseline.doiron@aphp.fr
      • Le Mans, Francia
        • Centre Hospitalier du Mans
        • Contacto:
          • Johann ROSE, Medical Doctor
          • Número de teléfono: +33 2 44 71 07 50
          • Correo electrónico: jrose@ch-lemans.fr
      • Lille, Francia, 59037
        • Centre Hospitalier Régional Universitaire principal de la métropole lilloise
        • Contacto:
      • Marseille, Francia, 13385
        • AP-HM - Hôpitaux Universitaires de Marseille Timone
        • Contacto:
          • Enora DIDIER, Registered Nurse
          • Número de teléfono: +33 4 91 38 67 76
          • Correo electrónico: Enora.DIDIER@ap-hm.fr
      • Montpellier, Francia, 34295
        • Centre Hospitalier Universitaire de Montpellier
        • Contacto:
          • Christine BIRON ANDREANI, Medical Doctor
          • Número de teléfono: +33 4 67 33 77 71
          • Correo electrónico: c-biron@chu-montpellier.fr
      • Nantes, Francia, 44093
        • Centre Hospitalier Universitaire Hôtel-Dieu
        • Contacto:
      • Paris, Francia, 75679
        • AP-HP - Hôpital Cochin
        • Contacto:
          • Stéphanie AGBOLO, Registered Nurse
          • Número de teléfono: +33 1 58 41 20 13
          • Correo electrónico: stephanie.agbolo@aphp.fr
      • Poitiers, Francia, 86021
        • Centre Hospitalier Universitaire de Poitiers - Hôpital Jean Bernard
        • Contacto:
      • Pringy, Francia, 74374
        • Centre Hospitalier Annecy Gennevois
        • Contacto:
      • Rennes, Francia
        • Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou
        • Contacto:
      • Saint-Denis, Francia, 97400
        • Centre Hospitalier Universitaire de la Réunion
        • Contacto:
      • Saint-Etienne, Francia, 45055
        • Centre Hospitalier Universitaire de Saint Etienne - Hôpital Nord
        • Contacto:
      • Strasbourg, Francia, 67200
        • Centre Hospitalier Universitaire de Strasbourg - Hôpital de Hautepierre
        • Contacto:
      • Toulouse, Francia, 31059
        • Centre Hospitalier Universitaire de Toulouse - Hôpital Purpan
        • Contacto:
      • Tours, Francia, 37044
        • Centre Hospitalier Régional Universitaire de Tours - Hôpital Trousseau
        • Contacto:
          • Laurent ARDILLON, Medical Doctor
          • Número de teléfono: 033 2 47 47 46 15
          • Correo electrónico: L.ARDILLON@chu-tours.fr
      • Vandœuvre-lès-Nancy, Francia, 54500
        • Centre Hospitalier Régional Universitaire de Nancy - Hôpital Brabois
        • Contacto:
          • Céline CHENUEL, Registered Nurse
          • Número de teléfono: +33 3 83 15 37 84
          • Correo electrónico: C.CHENUEL@chru-nancy.fr
      • Pointe-à-Pitre, Guadalupe, 97110
        • Centre Hospitalier Universitaire de Pointe à Pitre - Hôpital Ricou
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

The study population consists of adult and minor patients with severe (FVIII <1%) or moderate (FVIII 1%-5%) hemophilia A receiving prophylactic treatment with emicizumab for more than 1 year-or parent caregivers (excluding healthcare professionals) for non-autonomous minor patients-who were previously autonomous in performing intravenous clotting factor injections prior to emicizumab initiation. Healthcare professionals (physicians and nurses) involved in the care of these patients will also be enrolled. Participants will be recruited during routine clinical follow-up visits across participating French hemophilia treatment centers

Descripción

Inclusion Criteria:

For autonomous adult patients (patient enrolled in the study):

  • Adult patient (>= 18 years old) with severe or moderate hemophilia A
  • Receiving prophylactic treatment with emicizumab for more than 1 year
  • Patient previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
  • Patient non-opposition obtained

For autonomous pediatric/minor patients (patient enrolled in the study):

  • Minor patient (< 18 years old) with severe or moderate hemophilia A
  • Receiving prophylactic treatment with emicizumab for more than 1 year
  • Patient previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
  • Patient non-opposition obtained
  • Non-opposition obtained from parents or legal guardians

For non-autonomous pediatric/minor patients (family caregiver enrolled in the study):

  • Parent caregiver of a child with severe or moderate hemophilia A receiving prophylactic treatment with emicizumab for more than 1 year
  • Parent previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
  • Parent caregiver non-opposition obtained

For healthcare providers:

  • Physician, nurse, or healthcare professional involved in the care of patients with severe or moderate hemophilia A at a participating center
  • Healthcare provider non-opposition obtained

Exclusion Criteria:

For autonomous adult patients:

- Patient not autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation

For autonomous pediatric/minor patients:

- Patient not autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation

For non-autonomous pediatric/minor patients:

- Parent caregiver who is a healthcare professional

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: OTHER
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Patients or Family Caregivers

Patients with severe or moderate hemophilia A (or family caregivers for pediatric) receiving emicizumab prophylaxis who were previously autonomous in performing intravenous clotting factor injections. Participants will complete a structured questionnaire assessing their perceived autonomy and self-efficacy

Healthcare Providers

Healthcare professionals (physicians, nurses) caring for patients with hemophilia A at participating centers. Participants will complete a specific questionnaire evaluating their perception of patients' potential loss of autonomy for intravenous injections and its impact on clinical management

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Proportion of Patients or Family Caregivers Reporting a Perceived Loss of Autonomy for Performing Intravenous Clotting Factor Injections
Periodo de tiempo: At baseline (single questionnaire completion)

Assessed using Question 9 of the study-specific patient/caregiver questionnaire (4-point Likert scale: "not at all autonomous", "slightly autonomous", "moderately autonomous", "completely autonomous"). Responses of "not at all autonomous", "slightly autonomous", or "moderately autonomous" will be classified as a perceived loss of autonomy. Expressed as absolute frequency and percentage of respondents

At baseline (single questionnaire completion)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Frequency of Clotting Factor Concentrate Use Under Emicizumab Prophylaxis
Periodo de tiempo: At baseline (single questionnaire completion)

Absolute and relative frequency (percentage) of patients requiring intravenous clotting factor concentrates (FVIII or bypassing agents) while receiving emicizumab prophylaxis, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients Keeping Clotting Factor Concentrates at Home
Periodo de tiempo: At baseline (single questionnaire completion)

Percentage of patients who report having clotting factor concentrates (FVIII or bypassing agents) stored at home, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients or Caregivers Reporting Anticipated Difficulties With Performing a Future Intravenous Injection
Periodo de tiempo: At baseline (single questionnaire completion)

Percentage of patients or family caregivers who report experiencing or anticipating difficulties in performing a subsequent intravenous clotting factor injection, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Types of Difficulties Encountered During Intravenous Clotting Factor Injections
Periodo de tiempo: At baseline (single questionnaire completion)

Categorization and percentage distribution of specific technical or psychological difficulties reported by patients or family caregivers when performing intravenous injections, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients or Caregivers Expressing a Need for Home Nursing Assistance
Periodo de tiempo: At baseline (single questionnaire completion)

Percentage of patients or family caregivers reporting the need for a community nurse (IDE) to perform repeated intravenous clotting factor injections, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients Expressing a Need for a Therapeutic Patient Education Program
Periodo de tiempo: At baseline (single questionnaire completion)

Percentage of patients reporting the need for therapeutic education sessions to maintain their autonomy in performing intravenous clotting factor injections, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients or Caregivers Expressing a Need for Initial Intravenous Injection Training
Periodo de tiempo: At baseline (single questionnaire completion)

Percentage of patients or family caregivers reporting the need for initial training to learn how to perform intravenous clotting factor injections, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Frequency and Quantity of Unused Expired Clotting Factor Concentrates at Home
Periodo de tiempo: At baseline (single questionnaire completion)

Absolute and relative frequency (percentage) of patients having unused expired FVIII concentrates or bypassing agents at home, along with the total number of expired doses reported via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients or Caregivers Reporting an Impact of Perceived Loss of Autonomy on Bleeding Event Management
Periodo de tiempo: At baseline (single questionnaire completion)

Absolute and relative frequency (percentage) of patients or family caregivers reporting that their perceived loss of autonomy negatively affected the management of an acute bleeding episode, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Healthcare Providers Supporting the Maintenance of Patient or Caregiver Autonomy for Intravenous Injections
Periodo de tiempo: At baseline (single questionnaire completion)

Percentage of healthcare professionals who consider it necessary to maintain patients' or family caregivers' autonomy for intravenous administration of clotting factor concentrates, assessed via the healthcare provider questionnaire

At baseline (single questionnaire completion)
Proportion of Healthcare Providers Supporting the Maintenance of Clotting Factor Concentrates at Home
Periodo de tiempo: At baseline (single questionnaire completion)

Percentage of healthcare professionals who consider it necessary to keep emergency clotting factor concentrates at patients' homes, assessed via the healthcare provider questionnaire

At baseline (single questionnaire completion)
Proportion of Healthcare Providers Perceiving a Delay in Bleeding Management Due to Reduced Patient Autonomy
Periodo de tiempo: At baseline (single questionnaire completion)

Percentage of healthcare professionals who consider that a decreased sense of autonomy for performing intravenous injections delays the management of acute bleeding episodes, assessed via the healthcare provider questionnaire

At baseline (single questionnaire completion)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Nicolas GUERIN, Registered Nurse, Centre Hospitalier Universitaire de Caen - Centre de Ressources et de Compétences Maladies Hémorragiques Rares

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

15 de enero de 2027

Finalización primaria (Estimado)

30 de junio de 2028

Finalización del estudio (Estimado)

30 de junio de 2028

Fechas de registro del estudio

Enviado por primera vez

13 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

13 de noviembre de 2026

Publicado por primera vez (Actual)

18 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

13 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir